Tumor News and Research

RSS

Rosetta Genomics announces USPTO notice of allowance for Sanger hsa-miR-451

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, announced today the receipt of a new notice of allowance from the United States Patent and Trademark Office ("USPTO") for U.S. patent application 11/418,870, including claims related to Sanger hsa-miR-451. miR-451 is used in the Company's miRview™ mets test, which accurately identifies the primary tumor site in patients with metastatic cancer and Cancer of Unknown Primary (CUP).

11 May 2010

Limiting fat intake to below 20% can reduce risk of breast cancer recurrence by 24%

When one of the country's foremost physicians—people like Dr. Andrew Weil—need someone to care for their friends and family dealing with cancer, the man they turn to is Keith Block, M.D. "I believe in Keith's program and would head to the Block Center if I were facing a diagnosis of cancer. It is where I have and will continue to send my friends and family," said Dr. Weil.

11 May 2010

Advanced radiation techniques treat head and neck cancer, reduce swallowing complications

Researchers at the University of Michigan Comprehensive Cancer Center have applied advanced radiation techniques for head and neck cancer to avoid treating critical structures that affect swallowing and eating.

11 May 2010

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the first quarter ended March 31, 2010.

11 May 2010

Research may aid in developing new cancer therapies

Immortality and uncontrolled cell division are the fundamental differences between cancer cells and normal cells.

11 May 2010

Researchers develop new type of drug to kill non-Hodgkin lymphoma tumor cells

Three researchers who are recipients of a collaborative grant from the Samuel Waxman Cancer Research Foundation have developed a new type of drug designed to kill non-Hodgkin lymphoma tumor cells. The breakthrough could lead to potential non-toxic therapies for cancer patients. The Foundation-funded investigators include Ari Melnick, M.D., of Weill Cornell Medical College, Alexander MacKerell, Ph.D., of the University of Maryland and Gilbert Priv-, Ph.D., of the University of Toronto.

11 May 2010

UC San Diego researchers discover potential new treatment for familial adenomatous polyposis

A team of University of California, San Diego School of Medicine researchers has discovered that common intestinal bacteria appear to promote tumor growths in genetically susceptible mice, but that tumorigenesis can be suppressed if the mice are exposed to an inhibiting protein enzyme.

10 May 2010

CE 3D US creates spatial view for hemodynamic and morphologic evaluation of focal liver tumors

Recently, contrast-enhanced (CE) ultrasound (US) appeared as an important modality to show the vascularity in the areas of interest, and has been used widely in clinical diagnosis of liver lesions. Three dimensional ultrasonography (3D US) allows three orthogonal planes to spatially demonstrate the features of subjects, which has been frequently used in fetal US.

10 May 2010

UT Southwestern offers advanced lung-cancer patients free screenings of tumors for genetic mutations

UT Southwestern Medical Center is the only site in North Texas participating in a national study that offers advanced lung-cancer patients free screenings of their tumors for genetic mutations, some of which might be targets for treatment with existing or experimental therapies.

10 May 2010

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

New research by scientists at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute suggests that a drug currently approved to treat erectile dysfunction may significantly enhance the delivery of the anti-cancer drug Herceptin to certain hard-to-treat brain tumors.

10 May 2010

Double-balloon endoscopy reveals intestinal lipomas within jejunal duplication cysts

Lipoma of the small intestine is a benign tumor of mesenchymal origin which is mostly found by chance during gastrointestinal investigation. Invaginations account for 2/3 of small bowel occlusion caused by up to 80% of tumors and the lipoma is the most frequent benign tumor that causes invagination in its submucous polypoid and it is in more or less scissile form.

10 May 2010

Animal study reveals intestinal bacteria can promote tumor growth

10 May 2010

A cutting-edge symposium sheds light on the possibilities of molecular neuroimaging

SNM's Molecular Imaging Center of Excellence wrapped up its Molecular Neuroimaging Symposium today in Bethesda, Md., at the Natcher Auditorium of the National Institutes of Health (NIH).

10 May 2010

Report: 34 C>G of PPAR-γ gene might be a potential therapeutic target for colon cancer

Colorectal cancer is one of the major causes of cancer death in the developed countries. Accumulated evidences indicate that lipid metabolism, especially the one in the arachidonic acid -pathway, appears to play a critical role in the development of CRC.

7 May 2010

Chemical changes in genetic material regulate activity of many genes

Chemical changes in the genetic material, known as epigenetic modifications, regulate the activity of many genes. Thus, attachment of methyl groups to DNA often inactivates important cellular growth brakes. Therefore, this process called methylation is believed to be a major cause of uncontrolled division of cancer cells. Specific enzymes, the DNA methyltransferases, are responsible for methylation.

7 May 2010

Researchers investigate aberrant expression of nuclear matrix proteins in gastric cancer cells

Gastric cancer is the most common malignant gastrointestinal cancer and accounts for 25% of cancer deaths. Nuclear matrix, a filamentous protein framework for eukaryotic cellular chromatin, closely relates to DNA duplication and transcription. Research on nuclear matrix proteins will provide insight into how tumors developed.

7 May 2010

Threshold Pharmaceuticals reports $6.0M net loss for first-quarter 2010

Threshold Pharmaceuticals, Inc., today reported financial results for the first quarter ended March 31, 2010.

7 May 2010

Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010

Ardea Biosciences, Inc. a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), reported recent accomplishments and financial results for the first quarter ended March 31, 2010.

7 May 2010

Investment report on Keryx Biopharmaceutical from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Keryx Biopharmaceutical Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.

7 May 2010

Researchers analyze relationship between extent of resection and outcome in patients with glioblastoma

Gliomas arise from the supporting cells of the brain, called the glia. These cells are subdivided into astrocytes, ependymal cells and oligodendroglial cells (or oligos). These tumors are graded from the lowest grade 1 to highest grade 4, with glioblastoma multiforme being the highest grade and deadliest type of glioma.

7 May 2010

Tumor News and Research

Rosetta Genomics announces USPTO notice of allowance for Sanger hsa-miR-451

Limiting fat intake to below 20% can reduce risk of breast cancer recurrence by 24%

Advanced radiation techniques treat head and neck cancer, reduce swallowing complications

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Research may aid in developing new cancer therapies

Researchers develop new type of drug to kill non-Hodgkin lymphoma tumor cells

UC San Diego researchers discover potential new treatment for familial adenomatous polyposis

CE 3D US creates spatial view for hemodynamic and morphologic evaluation of focal liver tumors

UT Southwestern offers advanced lung-cancer patients free screenings of tumors for genetic mutations

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

Double-balloon endoscopy reveals intestinal lipomas within jejunal duplication cysts

Animal study reveals intestinal bacteria can promote tumor growth

A cutting-edge symposium sheds light on the possibilities of molecular neuroimaging

Report: 34 C>G of PPAR-γ gene might be a potential therapeutic target for colon cancer

Chemical changes in genetic material regulate activity of many genes

Researchers investigate aberrant expression of nuclear matrix proteins in gastric cancer cells

Threshold Pharmaceuticals reports $6.0M net loss for first-quarter 2010

Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010

Investment report on Keryx Biopharmaceutical from MicroStockProfit.com

Researchers analyze relationship between extent of resection and outcome in patients with glioblastoma

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News